ArticleCancer immunology, immunotherapy : CII2022
CD74
Article in Cancer immunology, immunotherapy : CII, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- Ascites reprograms innate lymphoid immune cells in ovarian cancer by promoting ILC2 enrichment and dysfunctional NK-cell states.Journal for immunotherapy of cancer · 2026Article
- IFDlong: a model-based isoform and fusion detector for accurate annotation and quantification of long-read RNA-seq data.Genome biology · 2026Article
- Lactate-induced metabolic reprogramming of TAMs impairs antigen presentation capacity via C/EBPα-CD74 axis in oral squamous cell carcinoma.Clinical and translational medicine · 2026Article
- Single-cell and spatial transcriptomic profiling reveals distinct tumor microenvironment dynamics in cervical adenocarcinoma and squamous cell carcinoma.Communications biology · 2025Article
- Integrating single-cell RNA sequencing and artificial intelligence for multitargeted drug design for combating resistance in liver cancer.NPJ precision oncology · 2025Article
- Article
- The IFN-high phenotype: A biomarker-driven breakthrough in colorectal cancer treatment.Cell reports. Medicine · 2025Article
- Prognostic effect of CD74 and development of a radiomic model for predicting CD74 expression in non-small cell lung cancer.Frontiers in medicine · 2025Article
- Article
- Harnessing Macrophages in Cancer Therapy: from Immune Modulators to Therapeutic Targets.International journal of biological sciences · 2025Review
- Article
- CD74 facilitates immunotherapy response by shaping the tumor microenvironment of hepatocellular carcinoma.Molecular medicine (Cambridge, Mass.) · 2024Article
- Integrated multi-omics profiling landscape of organising pneumonia.Clinical and translational medicine · 2024Article
- Therapeutic targets of formononetin for treating prostate cancer at the single-cell level.Aging · 2024Article
- Insights into the prognostic value and immunological role of CD74 in pan-cancer.Discover oncology · 2024Article
- Article
- Unravelling immune microenvironment features underlying tumor progression in the single-cell era.Cancer cell international · 2024Review
- Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanoma.Nature cancer · 2024Article
- Article
- CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.Cancer immunology, immunotherapy : CII · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
CD74 was initially thought to participate mainly in antigen presentation as an MHC class II chaperone. Recent studies have shown that CD74 plays an important role within the cell and throughout the immune system in a wide spectrum of neoplasms. However, the role of CD74 in hepatocellular carcinoma (HCC) remains elusive. In this study, HCC tissues from Zhongshan Hospital and data from The Cancer Genome Atlas (TCGA) were obtained and analyzed. Immunohistochemistry, flow cytometry, and single-cell RNA sequencing (scRNA-seq) were performed to detect the characteristics of CD74
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.